SAN DIEGO, Aug. 18, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Unicycive Therapeutics, Inc. (NASDAQ: UNCY) securities between March 29, 2024 and June 27, 2025. Unicycive is a clinical-stage...
Related Questions
How likely is the class action to result in a settlement or judgment that could materially affect UNCY's share price?
What potential impact does the lawsuit have on Unicycive's ongoing clinical programs and financing needs?
How does the market's reaction to similar biotech class-action filings inform expectations for UNCY's short‑term volatility?